← The Wire
ASMBNasdaq
ASSEMBLY BIOSCIENCES, INC.
Pharmaceutical Preparations · DE · CIK 1426800
Developing innovative therapeutics targeting serious viral diseases like herpes, hepatitis delta, and hepatitis B
red 8-K · 90d
$455M
Market cap
$26.96
Last close
+0.8%
1D
+7.2%
5D
236K
Volume
Price · last 39 sessions-3.1%
May 4L $22.26 · H $31.72Jun 29
360
Total filings
Jun 5, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteJun 5, 2026SC 13D/ASC 13D/AMay 27, 20268-KMaterial Agreement · Company UpdateMay 26, 2026424B5424B5May 26, 2026424B5424B5May 22, 20268-KReg FD Disclosure · Company UpdateMay 22, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEFA14ADEFA14AApr 22, 2026DEF 14ADEF 14AApr 22, 20268-KExecutive ChangeMar 30, 202610-K10-KMar 19, 20268-KResults of OperationsMar 19, 20268-KReg FD Disclosure · Company UpdateDec 8, 202510-Q10-QNov 10, 20258-KResults of OperationsNov 10, 20258-KMaterial Agreement · Equity IssuanceAug 11, 2025424B5424B5Aug 11, 2025424B5424B5Aug 11, 20258-KReg FD Disclosure · Company UpdateAug 8, 202510-Q10-QAug 6, 20258-KResults of Operations · Company UpdateAug 6, 20258-KCompany UpdateJun 25, 20258-KExecutive Change · Shareholder VoteJun 9, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 8, 2025DEFA14ADEFA14AApr 23, 2025DEF 14ADEF 14AApr 23, 202510-K10-KMar 20, 20258-KResults of OperationsMar 20, 20258-KCompany UpdateFeb 20, 20258-KMaterial Agreement · New Debt / ObligationJan 3, 20258-KCompany UpdateDec 26, 20248-KMaterial Agreement · Equity IssuanceDec 19, 20248-KBylaw AmendmentDec 13, 2024SC 13GSC 13GNov 14, 20248-KMaterial AgreementNov 7, 2024424B5424B5Nov 7, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 20248-KCompany UpdateSep 23, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 8, 20248-KMaterial Agreement · Equity IssuanceJun 18, 2024424B5424B5Jun 18, 20248-KExecutive Change · Shareholder VoteJun 3, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 8, 2024DEFA14ADEFA14AApr 17, 2024DEF 14ADEF 14AApr 17, 202410-K10-KMar 28, 20248-KResults of OperationsMar 28, 20248-KExecutive ChangeMar 15, 20248-KSecurity-Holder Rights · Bylaw AmendmentFeb 13, 20248-KShareholder Vote · Company UpdateFeb 2, 20248-KAgreement TerminatedJan 17, 2024DEFA14ADEFA14ADec 21, 2023DEF 14ADEF 14ADec 21, 20238-KExecutive Change · Company UpdateDec 7, 202310-Q10-QNov 8, 20238-KResults of OperationsNov 8, 2023SC 13DSC 13DOct 31, 20238-KMaterial Agreement · Equity IssuanceOct 17, 20238-KDelisting NoticeSep 29, 202310-Q10-QAug 9, 20238-KResults of OperationsAug 9, 20238-KMaterial Agreement · New Debt / ObligationAug 7, 20238-KExecutive Change · Shareholder VoteMay 30, 202310-Q10-QMay 4, 20238-KResults of OperationsMay 4, 20238-KCompany UpdateApr 18, 2023DEFA14ADEFA14AApr 12, 2023DEF 14ADEF 14AApr 12, 202310-K10-KMar 22, 20238-KResults of Operations · Company UpdateMar 22, 20238-KCompany UpdateFeb 15, 20238-KCompany UpdateDec 19, 20228-KExecutive Change · Bylaw AmendmentDec 12, 202210-Q10-QNov 8, 20228-KResults of OperationsNov 8, 2022
Insider Activity
In the 90 days to Mar 30, 2026: 2 sold $14K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 30, 2026 | Bjorkquist Jeanette MPFO and PAO | Sell | 312 | $26.65 | $8K |
| Mar 30, 2026 | White Nicole SChief Manufacturing Officer | Sell | 188 | $26.65 | $5K |
| Mar 30, 2026 | Bjorkquist Jeanette MPFO and PAO | Sell | 16 | $27.49 | $440 |
| Mar 30, 2026 | White Nicole SChief Manufacturing Officer | Sell | 9 | $27.49 | $247 |
| Aug 8, 2025 | Gilead Sciences, Inc.TenPercentOwner | Buy | 2,295,920 | — | — |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance